Welcome to our dedicated page for Phibro Animal Health Corporation news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health Corporation stock.
Phibro Animal Health Corporation (Class A, symbol: PAHC) is a leading global company specializing in animal health and mineral nutrition. With over 40 years of experience, Phibro is dedicated to meeting the rising demand for animal protein by focusing solely on animals used in food production. The company offers a comprehensive range of products for poultry, swine, beef and dairy cattle, and aquaculture.
Phibro's core business involves the development, manufacturing, and marketing of products designed to prevent, control, and treat animal diseases, enhance nutrition, and contribute to balanced mineral nutrition. Their product portfolio includes antibacterials, anticoccidials, nutritional specialty products, and vaccines. The company's operations are divided into three segments: Animal Health, Mineral Nutrition, and Performance Products, with the Animal Health segment being the primary revenue driver.
In the fiscal year ending June 30, 2017, Phibro reported net sales of $764 million. The company employs over 1,400 professionals who are committed to delivering value-based solutions to livestock producers, helping them maintain and enhance the health of their animals. Phibro's products are sold both in the United States and internationally, demonstrating its significant global footprint.
Recent achievements and ongoing projects by Phibro include the development of new vaccines and nutritional specialties aimed at improving animal health and productivity. The company continues to partner with various stakeholders in the livestock industry to innovate and provide sustainable solutions.
Phibro's financial condition remains robust, supported by consistent revenue streams from its diversified product offerings. The company’s focus on research and development underscores its commitment to advancing animal health technologies and addressing the evolving needs of the livestock industry.
For the latest news and updates, Phibro Animal Health Corporation remains a key player in the animal health sector, reflecting its dedication to enhancing the well-being of food animals globally.
Phibro Animal Health Corporation (NASDAQ: PAHC) has appointed Alejandro Bernal as a Class III director, effective immediately, increasing the Board membership to nine, with six independent directors. Bernal, CEO of PetDx and former President of Mars Veterinary Health, brings extensive experience in the animal health sector. Additionally, the Board declared a quarterly cash dividend of $0.12 per share on Class A and Class B common stock, payable on March 22, 2023, to shareholders of record by March 1, 2023.
Phibro Animal Health Corporation (NASDAQ: PAHC) will report its second quarter financial results on February 8, 2023, following the market's close. A conference call will be held on February 9, 2023, at 9:00 AM ET, giving interested parties access via a live webcast or by calling in. This provides an opportunity for investors to gain insights into the company's financial health and future outlook. For more details, visit Phibro's investor relations page.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its financial results for Q1 2023, ending September 30, 2022. Net sales reached $232.5 million, an 8% increase year-over-year, driven mainly by Animal Health and Mineral Nutrition segments. However, net income fell 41% to $3.9 million, with diluted EPS dropping to $0.10. Adjusted EBITDA slightly declined to $22.1 million. The company reiterated guidance for net sales but revised forecasts for net income and EPS, reflecting increased interest rates and changes in tax legislation.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ: PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend will be payable on December 21, 2022, to stockholders of record at the close of business on November 30, 2022. Phibro is a global leader in animal health and nutrition, dedicated to providing solutions that enhance animal health.
Phibro Animal Health Corporation (NASDAQ: PAHC) will announce its first quarter financial results on November 9, 2022, after market close. Management will host a conference call on November 10, 2022, at 9:00 AM ET. Interested parties can access the call and presentation at investors.pahc.com. A replay will be available two hours post-event. Phibro is a diversified animal health and mineral nutrition company focused on enhancing animal health for livestock and companion animals.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its Q4 and fiscal year 2022 results, highlighting a 16% rise in net sales to $255.3 million but a 56% drop in net income to $7.5 million. The full year 2022 saw net sales grow by 13% to $942.3 million, yet net income fell 10% to $49.2 million. The company expects FY 2023 net sales between $960 million and $1 billion and diluted EPS of $1.11 to $1.21. Adjusted EBITDA rose 3% year-over-year to $111.1 million. Phibro plans strategic investments despite ongoing inflationary pressures.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Morgan Stanley Global Healthcare Conference on September 14, 2022, at 9:10 AM ET in New York. CFO Damian Finio and EVP Daniel Bendheim will present to financial analysts and investors. The live audio presentation can be accessed on their Investor Relations Website, with a replay available afterward. Phibro is dedicated to providing health solutions for livestock and companion animals, reinforcing its position as a global leader in animal health and nutrition.
Phibro Animal Health Corporation (NASDAQ:PAHC) will announce its fourth quarter and fiscal year 2022 financial results on August 24, 2022, post-market. A conference call will follow on August 25, 2022, at 9:00 AM ET, which can be accessed via phone or webcast. The company is a global leader in animal health and nutrition solutions, dedicated to supporting livestock and companion animal care.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) declared a quarterly cash dividend of
Phibro Animal Health Corporation (NASDAQ:PAHC) has partnered with Rejuvenate Bio, Inc. to develop a gene therapy for Mitral Valve Disease (MVD) in dogs, a condition affecting approximately 7% of all canines, and up to 80% in breeds like Cavalier King Charles Spaniels. The aim is to create a treatment that not only halts MVD's progression but also reverses existing cardiac damage. Rejuvenate Bio plans to seek conditional approval as early as 2023, leveraging research from Harvard Medical School and the Wyss Institute to address age-related diseases.
FAQ
What is the current stock price of Phibro Animal Health Corporation (PAHC)?
What is the market cap of Phibro Animal Health Corporation (PAHC)?
What does Phibro Animal Health Corporation do?
Which animals does Phibro's products cater to?
What are the main product categories of Phibro Animal Health Corporation?
How many employees does Phibro Animal Health Corporation have?
How much revenue did Phibro report for the fiscal year ending June 30, 2017?
What are the primary segments of Phibro's operations?
Where does Phibro sell its products?
What recent projects is Phibro involved in?
Who are Phibro's primary customers?
What drives Phibro's revenue?
